PRIMARY BREAST CANCER THERAPY GROUP

作为原发性乳腺癌治疗组的参与机构 （NSABP），我们提供了来自进入各种方案的患者的数据， 并将继续为方案B-06、11、12、13、14提供数据， C 01和R 01 本申请寻求资金：（a）允许 在正在进行的方案中继续增加患者;（B）参与 与评价和执行本战略有关的国家生物多样性战略和方案活动 试验，设计新的协议，规划未来，教育 增加病人人数并与总部合作;（c） 参与NSABP接受的临床研究，特别是 与辅助治疗对我们的影响相关的临床研究 （4）调查影响患者依从性的因素 治疗方案 虽然对所有患者进行了各种方案的随访， 也将是一项重要的活动。 方案B-06是一项试验， 乳腺部分切除术与全乳切除术的价值。 我们的努力将 针对那些社区医院和肿瘤团队， 没有为这项非常重要的研究贡献患者。 我们已经计划好了 每四个月举办一次工作坊， 外科医生所需的技术。 方案B-11和12评价 II期乳腺癌患者使用更积极的治疗。 在 在这项试验中，我们对接受 阿霉素。 一个心脏病小组会评估每一个服用这种药的病人 治疗前和治疗后定期使用非侵入性 技术. 这是非常重要的，因为优秀的 我们的患者的体能状态可能会因意外改变 心脏毒性 方案B-13和14将研究I期患者， 将根据他们的ER状态测试治疗与未治疗。 我们将一如既往，继续为 原发性结直肠癌的辅助方案。 最后，目标是 该议定书是为了增加我们的多学科方法， 临床试验机构，并涉及尽可能多的社区医生 尽可能地增加患者的增加，并创造一个环境， 对于收集有关乳腺和肠道的重要生物学数据至关重要 癌

As participating institution in the primary breast cancer therapy group (NSABP), we have contributed data from patients entering various protocols, and will continue to contribute data to protocols B-06, 11, 12, 13, 14, C-01 and R-01. The present application seeks funding: (a) to permit continued patient accrual in on-going protocols; (b) to participate in the NSABP activities relating to evaluation and execution of the present trials, design of new protocols, planning for the future, education for increase of patient accrual and cooperation with the headquarters; (c) participation in clinical research accepted by NSABP and particularly clinical investigation related to the effect of adjuvant treatment on our own patients; (4) investigating factors that affect compliance with therapeutic regimen. Though follow-up of all patients on various protocols will be an essential activity as well. Protocol B-06 is a trial to compare the worth of segmental mastectomy with total mastectomy. Our efforts will be directed toward those community hospitals and oncology teams which have not contributed patients to this very important study. We have made a plan to hold workshops every four months which will introduce the community surgeons to the required techniques. Protocols B-11 and 12 evaluate patients with breast cancer Stage II using more aggressive treatment. In this trial we are performing special evaluations of the patients receiving Adriamycin. A cardiology team will evaluate every patient on this drug before treatment and thereafter at periodic intervals using non-invasive techniques. This is of great importance because of the excellent performance status of our patients which may be altered by unexpected cardiotoxicity. Protocols B-13 and 14 will study patients with Stage I and treatment -vs- no treatment will be tested according to their ER status. We will continue to make a substantial contribution as in the past to the adjuvant protocols for primary colo-rectal carcinoma. Finally, an aim of this protocol is to increased the multidisciplinary approach of our institution in clinical trials, and to involve as many community physicians as possible to enhance patient accrual and to create an environment essential to the gathering of important biological data on breast and bowel cancer.